Black AYA Cancer Survivors Have Fewer Live Births Than Other AYA Survivors
Black adolescent and young adult cancer survivors may be less likely than their peers of other races and ethnicities to have a live birth after cancer, data suggest.
Black adolescent and young adult cancer survivors may be less likely than their peers of other races and ethnicities to have a live birth after cancer, data suggest.
In an update of a Norwegian trial, researchers found that long term, salvage reirradiation for locally recurrent prostate cancer was feasible and associated with good…
Leonardo Provenzano, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, examines the use of machine learning to predict early progression in patients with HR-positive,…
Salvage treatment with nivolumab plus ipilimumab following progression on nivolumab alone led to significant treatment-free survival in advanced ccRCC.
Salvage treatment with nivolumab plus ipilimumab following progression on nivolumab alone led to significant treatment-free survival in advanced ccRCC.
Supported by an independent educational grant from Genmab US, Inc. and AbbVie Join us for a symposium on bispecific antibodies for relapsed-refractory diffuse large B-cell…
Nivolumab plus concurrent chemoradiotherapy, followed by nivolumab plus ipilimumab, did not improve PFS in unresectable stage III NSCLC.
Rebecca Robinson, MRCP, MBBS, MRFSEM, Marylebone Health Group (CHHP), London, UK, comments on the role of exercise in cancer care, highlighting the importance of physical…
A retrospective analysis showed that metastasectomy plus radical nephrectomy could improve survival in patients with metastatic non–clear cell RCC.
Joaquim Bellmunt, MD, PhD, discusses the impact of enfortumab vedotin plus pembrolizumab on the treatment paradigm in first-line urothelial cancer.
Petros Grivas, MD, PhD, discusses the significance of the phase 3 JAVELIN Bladder 100, EV-302, and CheckMate 901 trials in urothelial cancer.